Pα+ Psychedelic Bulletin #203: Norway Considers Funding Off-Label Ketamine for TRD; Longevity Crowd Hypes Psilocybin Study; Will State-Legal Psychedelics Eat Psychedelic Pharma’s Lunch?

The Norwegian Medical Products Agency (Direktoratet for medisinske produkter or DMP) has published its health technology assessment (HTA) of intravenous ketamine for treatment-resistant depression (TRD). It said that it was commissioned to conduct the review in the context of growing interest in ketamine’s potential in the disorder. The agency reviewed 19 randomised controlled trials…

Source